Studies have revealed that dysregulation in gene expression is one of the main aspects of multiple sclerosis (MS) pathogenesis. Although the molecular pathways underlying the immunomodulatory role of vitamin D (VD) in MS is not completely elucidated, VD has more recently become a topic of interest in immune regulation and is widely administered to patients with MS as an immunomodulatory supplement. Long non-coding RNAs (lncRNAs) are known to play important roles in regulation of gene expression via different mechanisms. Given that VD-related genes are regulated by epigenetic mechanisms, here we aimed to evaluate the role of VD in combination with HOTAIR and ANRIL lncRNAs using in vivo, in vitro and in silico experiments in MS pathogenesis. Our data revealed that HOTAIR but not ANRIL lncRNA is probably involved in the pathogenesis of MS and experimental autoimmune encephalomyelitis through an unclear mechanism and it seems that by affecting the expression, inflammation and VD can influence HOTAIR-related mechanisms, which require further study.
Introduction
Long non-coding RNAs (lncRNAs), a new class of gene modulators, have been implicated in the regulation of a broad range of physiological immune processes, including activation of innate immune responses, T-cell development, differentiation and activation. 1 Previous studies have shown aberrant transcription of different lncRNAs in response to activation of immune cells in various pathological conditions such as cancers and neurological diseases. 2 Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by autoimmune demyelination and neurodegeneration. Although the aetiology of MS remains elusive, the mechanisms underlying disease presumably result from a complex interaction between genetic and environmental factors such as low vitamin D (VD) status, Epstein-Barr virus infection and smoking. Although the molecular pathways underlying the immunomodulatory role of VD in MS are not completely elucidated, VD has recently become a topic of interest in immune regulation and is often administered to patients with MS as an immunomodulatory supplement. 3 Previous studies have shown a protective role of VD in MS pathogenesis, exerted through its well-known immunomodulatory roles such as regulation of cytokine production and T-cell proliferation.
3,4 VD (1,25(OH) 2 D3) effects seem to be primarily mediated by its cognate receptor, the nuclear vitamin D receptor (VDR). 5 VD supplementation of patients with MS has been shown to regulate cytokine production and T-cell proliferation. VDR is a nuclear receptor that heterodimerizes with the retinoid X receptor, which after ligation with 1,25(OH) 2 D recognizes vitamin D response elements (VDREs) within regulatory regions of targeted genes. 6 Importantly, several studies have revealed that VD can impact the expression of lncRNAs 7, 8 and that peripheral blood mononuclear cells (PBMCs) and serum of patients with MS exhibit altered levels of lncRNAs compared with controls. [9] [10] [11] Studies aiming to understand the mechanisms underpinning lncRNA regulation of gene expression have greatly benefited from the discovery of HOX transcript antisense intergenic RNA (HOTAIR), a lncRNA molecule encoded within the HoxC gene cluster on chromosome 12 and transcribed in an antisense manner with respect to the canonical HoxC genes. 12 Rinn et al. 12 have shown that HOTAIR silences the HoxD locus of chromosome 2 by interacting with chromatin-remodelling enzymes. Interestingly, a recent study has found that keratinocytes lacking VDR display altered expression of lncRNAs, including overexpression of HOTAIR. 7 Another lncRNA, ANRIL (antisense lncRNA of the INK4 locus), has gained attention in inflammatory disorders, because it has been associated with inflammatory disorders (PMID: 23813974) and implicated in the regulation of inflammatory responses (PMID: 26618242). ANRIL, located within the CDKN2B-CDKN2A gene cluster spanning across ã 30 to 40 kb region at chromosome 9p21, reportedly alters chromatin and subsequently transcription of target genes by affecting the chromatin-remodelling complexes PRC1 and PRC2. 13 Here, we aimed to examine the role of HOTAIR and ANRIL lncRNAs in MS pathogenesis in relation to VD levels using a pilot clinical VD supplementation trial of patients with MS as well as in vitro and in vivo investigations in mouse MS-like disease experimental autoimmune encephalomyelitis (EAE).
Materials and methods

In silico analysis of VDRE binding sites
To test the existence of putative VDREs in regulatory sequences of human and mouse HOTAIR and ANRIL genes, we used ConSite (http://consite.genereg.net/cgibin/consite) 14 and Jasper (http://jaspar.genereg.net/) 15 with a profile score threshold of 80%.
Human cohort and VD supplementation
Forty-two patients with relapsing-remitting MS in the MS Research Centre of Sina Hospital of Tehran University of Medical Sciences, Tehran, Iran were clinically diagnosed according to McDonald's criteria by an expert neurologist and registered in this pilot clinical trial. The informed consent was obtained from all participants and the investigation was performed in keeping with the Helsinki declaration on research with human participant. Based on the literature, 16 we considered patients who had a VD level < 20 ng/ml as deficient and supplemented with 50 000 IU/ week vitamin D3 for 8 weeks. Moreover, we selected 32 age-and gender-matched healthy controls, all of them deficient for VD and showing no sign of inflammation or neurological disease. This trial was approved by the medical ethics committee of Tarbiat Modares University and was registered with the Iranian Registry of Clinical Trials (ID: IRCT2014011216181N1). Before and after supplementation with VD, whole blood samples were obtained from all participants and the level of 25-hydroxyvitamin D was immediately measured using ELISA with a 25-hydroxyvitamin D detection kit (Immunodiagnostic Systems, Boldon, UK), whereas PBMCs were isolated and stored for subsequent RNA expression analyses.
EAE induction and clinical evaluation
All experiments were performed according to the guidelines of the local ethics committee on animal research. EAE was induced in 6-to 8-week-old C57BL/6 mice by subcutaneous injection of 200 lg myelin oligodendrocyte glycoprotein (MOG MEVGWYRSPFSRVVHLYRNGK) peptide (BioSynthesis Inc., Lewisville, TX) in 200 lg complete Freund's adjuvant (BD Diagnostics, Franklin Lakes, NJ) containing 5 mg/ml Mycobacterium tuberculosis under 4% isoflurane anaesthesia. Just after immunization as well as 48 hr later, mice were given an intraperitoneal injection of 500 ng pertussis toxin (Sigma Aldrich, St Louis, MO). Animals were daily monitored, weighed and scored for signs of neurological deficit. The following EAE score was applied: 0 = no clinical signs; 1 = tail paralysis; 2 = hind limb paresis; 3 = hind limb paralysis; 4 = fore limb paresis; 5 = moribund. Control mice were injected with everything except the MOG peptide. Animals were killed when the EAE group reached score 4, i.e. on the 19th day post-immunization. Mice were killed by decapitation and the spinal cord, cortex and cerebellum were immediately removed, frozen and stored for subsequent RNA extraction.
Cell culture and treatments
To evaluate the effects of VD (10, 30, 100 nm and 1 lm), recombinant human granulocyte-macrophage colonystimulating factor (rhGM-CSF) (10 lg/ml) and phytohaemagglutinin (PHA) (10 ng/ml) on the expression levels of selected genes, THP-1 cells were cultured in RPMI-1640 medium supplemented with 5% fetal bovine serum (Gibco, Waltham, MA), 2-mM L-glutamine, and 2-mM penicillinstreptomycin in 5% CO 2 at 37°for 4, 24 and 48 hr. Moreover, to assess the effects of patient serum on the expression levels of selected genes, we used fresh relapsing-remitting MS and secondary progressive MS sera passed through a sterile 0Á2-mm filter. THP-1 cells were cultured in RPMI-1640 medium supplemented with 10% filtered sera of patients, and 2-mM penicillin-streptomycin in 5% CO 2 at 37°for 4, 24 and 48 hr. In this case, cells cultured with sterile fresh sera from healthy control participants were considered as control. Treated cells (rhGM-CSF, PHA, relapsing-remitting MS serum and secondary progressive MS serum) were supplemented with 100 nm VD for the evaluation of its immunomodulatory role for 24 hr. All tests were performed in triplicates.
Gene expression analysis by real-time PCR RNA extraction were performed by RiboEX solution (GeneAll, Seoul, Korea) after PBMC isolation using a Ficoll-Paque solution gradient. First-strand cDNA synthesis was performed using 3 lg of purified total RNA by the 2-Steps RT-PCR kit (Vivantis, Oceanside, CA). All quantitative gene expression analyses were assessed in duplicates using EVAGREEN I master mix (Solis Biodyne, Tartu, Estonia). The relative expression of human HOTAIR and ANRIL lncRNAs and VDR, c-Myc and IL-1B mRNAs were normalized to GAPDH. The expression level of mouse Hotair lncRNA was normalized to Hprt as the endogenous control.
Statistical analysis
The normality of data was addressed using the ShapiroWilk test and the relative expression levels of selected genes were calculated by the DDCt method. Paired Student's t-test (patients with MS before versus after supplementation) and independent t-test (patients with MS versus controls) were performed to analyse the statistical differences in the expression levels of selected genes between groups. Correlation analysis were performed using Pearson and Spearman rank tests. A P-value <0Á05 was considered significant. Biomarker potential was assessed by receiver operating characteristic (ROC) analysis. One-way and two-way analyses of variance with Bonferroni post-hoc tests were used to determine if there were significant differences between cell groups assayed at different times following different treatments.
Results
In silico analysis showed putative VDREs at HOTAIR and ANRIL loci Using the Jasper and Consite algorithms, the A/GGG/ TTCAnnnA/GGG/TTCA and GA/GGTTCATnnnGTTCA sequences were considered as human and mouse VDRE consensus sequences, respectively, as previously shown. 17, 18 Previous studies have suggested that regulatory VDREs could locate distally, i.e. > 1 Mb, to the transcription starting site. 19 We analysed the entire genomic sequence of the human and murine HOTAIR and ANRIL genes as well as 5 kb upstream the transcription starting sites to include proximal promoter regions. Our analysis revealed two and three potential VDREs in the human HOTAIR and ANRIL genes, respectively, all of them were located within the intron 1 (Table 1) . In silico mapping analysis in the mouse genome failed to find any VDRE site in the Hotair gene. Of note, sequence information for the mouse Anril gene is currently unavailable -precluding us from investigating VDRE of this lncRNA in the mouse genome. These data suggest a possible regulation of HOTAIR and ANRIL lncRNAs by the VD pathway.
HOTAIR and ANRIL expression in VD-supplemented patients with MSand healthy controls
We examined the relationship between VD levels and HOTAIR and ANRIL expression in patients with MS and matched controls. Forty-two patients with relapsingremitting MS were registered in our VD3 supplementation clinical trial study with inclusion criteria according to the Expanded Disability Status Scale (EDSS) score (0-5), age (from 20 to 55 years old) and deficiency in VD level, as described previously and mentioned in more detail in Table 2 . 20 Ten out of the 42 patients with relapsing-remitting MS who started the supplementation, did not pursue the trial: four did not wish to continue the study and six were excluded from the trial because of relapse. All matched control individuals were VD-deficient. Measurement of the serum level of VD showed a significant increase in all patients with MS after the 8-week supplementation with the exception of two ATGTCAaagAGTTGA GGGTGAaaaACTTCA rs920778 [1] • influenced the expression of HOTAIR
GAGTCAaagGGTACC AGGACAacaAGTTTA AGTTCAcagTGTTCA rs10757278 [2] rs1333045 [3] • disrupts a binding site for STAT1
• influenced the expression of ANRIL • functionally affect the activity of the 9p21Á3 locus • influenced the expression of ANRIL • disrupts a binding site for Smad3
The table indicates from left to right, the chromosome number (Chr), the gene name, the number (#) of VDREs in the analysed genomic sequence, the location of the VDREs, the sequence of the VDREs consensus sequences; A/GGG/TTCAnnnA/GGG/TTCA (deviation from the consensus sequence (if present) is marked with a bold nucleotide), the identity of the single nucleotide polymorphisms(SNPs) which may affect the expression levels of host genes (based on literature), the location of SNPs (http://snpper.chip.org/). individuals whose serum levels surprisingly decreased. We next quantified VDR mRNA and HOTAIR and ANRIL lncRNA expression in PBMCs from VD-deficient patients with MS before and after VD supplementation and in matched healthy control individuals. We found significantly higher expression levels of HOTAIR lncRNA in VD-deficient (not supplemented) patients with MS compared with control individuals (P = 0Á004). We could not observe any significant difference in HOTAIR lncRNA expression levels in patients with MS after supplementation with VD compared with baseline levels (P = 0Á17). However, VD treatment resulted in a tendency toward lower HOTAIR expression, reaching similar levels to the healthy controls (Fig. 1a) . Changes in the expression of HOTAIR for all samples are shown in Fig. 1(b) . In contrast, there were no significant differences in the expression level of ANRIL lncRNA between groups, i.e. between cases and controls at any time-point of VD supplementation and within patients with MS before and after VD treatment ( Fig. 1c and d) . To gain insight into the link between VD levels and lncRNA expression, we stratified patients according to vitamin D3 level (Dvit D3 = 25-hydroxyvitamin D after treatment À 25-hydroxyvitamin D before treatment) (Dvit D3 level ≥ 30 ng/ml and Dvit D3 level < 30), gender and EDSS scores (EDSS ≥ 2Á5 and EDSS < 2Á5) ( Table 3) . Results indicated that the expression level of HOTAIR in VD-deficient patients with MS (before supplementation) were significantly different from those of controls in all the stratified groups except in men. Stratification of the patients did not allow us to detect any significant differences in the expression of ANRIL between groups. Interestingly, concomitant to the significant rise in the VD serum levels after supplementation, the expression of VDR mRNA significantly decreased after VD treatment (P = 0Á02) (Fig. 1e) . Using ROC curve analysis, we found that HOTAIR lncRNA expression may be a potential biomarker to discriminate patients with MS from control individuals (Fig. 1f) with the optimal cut-off value of 14Á53 (sensitivity = 46Á88% and specificity = 96Á77%). There were no significant correlations between the expression levels of HOTAIR and ANRIL lncRNAs and clinical features such as serum VD level (Fig. 2a) , EDSS scores (Fig. 2b) , disease duration (Fig. 2c) and age (Fig. 2d) . Moreover, correlations of HOTAIR and ANRIL lncRNAs expression with VDR mRNA expression did not yield any significant correlation (P > 0Á05). Altogether, our findings suggest a possible involvement of HOTAIR lncRNA in MS pathogenesis, and particularly in VDmediated immune processes.
Implication of Hotair but not Anril in the pathogenesis of EAE
We next sought to further explore the role of HOTAIR and ANRIL in the MS-like disease EAE in mice. To this aim, given the absence of VDRE in the analysed sequence of mouse Hotair, we examined Hotair and Anril expression in the central nervous systems of EAE mice without VD supplementation. Onset of EAE disease occurred at 10Á3 AE 0Á2 days after immunizations, parallel to a reduced weight of the animals, and disease symptoms reached a score of 4 after about 18 days post-immunization. Gene expression analysis revealed that the expression level of Hotair but not Anril was significantly decreased in the spinal cord (P = 0Á02) and cortex (P = 0Á032) and increased in cerebellum (P = 0Á028) in the EAE mice compared with the control mice (Fig. 3a) . This finding suggests a role of Hotair in neuroinflammatory and neurodegenerative processes underlying MS in a tissue-specific manner.
Expression of HOTAIR and ANRIL in vitro
We aimed to gain further insight into the regulation of HOTAIR and ANRIL lncRNAs by VD in vitro by exposing human monocyte-derived THP-1 cells to VD for various times (4, 24 and 48 hr). The expression of the VDR and c-Myc genes, two well-known early response genes to VD, were significantly induced after 24 hr of 100 nmol/ml VD exposure (fold changes of 5Á19 and 1Á9 of VDR and c-Myc, respectively) (Fig. 3b) . Evaluation of the expression levels of HOTAIR and ANRIL lncRNAs 4, 24 and 48 hr after treatment with various concentrations of VD did not show any significant difference in the expression level of these genes between treated and untreated cells (P > 0Á05, data not shown). We next investigated the effect of VD on HOTAIR and ANRIL expression 24 hr after THP-1 stimulation by rhGM-CSF and PHA (data as well as recombinant human interleukin-3 and PMA, data not shown). 21, 22 Treatment of cells with rhGM-CSF (Fig. 3c) and PHA (Fig. 3d) led to a significant increase of the known inflammatory marker IL-1b, this induction being significantly reduced by VD exposure. In contrast, we could not observe any effect of rhGM-CSF and PHA alone or in combination with VD on the expression of HOTAIR and ANRIL. To mimic the in vivo inflammatory environment found in patient 
(e) (f) Figure 1 . The effect of vitamin D (VD) supplementation on the expression levels of human HOTAIR and ANRIL long non-coding RNAs (lncRNAs) and VDR mRNA. We found a significant difference between the expression levels of HOTAIR (a, b) but not ANRIL (c, d) lncRNA before supplementation versus controls. Interestingly, the expression of VDR (e) significantly decreased before versus after supplementation. ROC curve analysis performed by plotting sensitivity versus (1 -specificity) for each threshold value (f). The area under the curve shows the ability of HOTAIR expression to differentiate non-supplemented patients with multiple sclerosis from controls **P < 0Á01, *P < 0Á05.
with MS, we exposed THP-1 cells to fresh sera from patients with relapsing-remitting MS (Fig. 3e ) and secondary progressive MS (Fig. 3f) with or without the addition of VD. Interestingly, exposure to patient sera AE VD could replicate the impact of rhGM-CSF and PHA on IL-1b, HOTAIR and ANRIL expression. Altogether, these data imply that expression of HOTAIR and ANRIL is probably not affected by VD and/or inflammation in THP-1 cells in vitro. Our findings further indicate that sera from patients with MS can represent a potent inflammatory milieu with similar effects to rhGM-CSF and PHA, this pro-inflammatory impact being further attenuated by VD.
Discussion
Even though the molecular mechanisms underlying VD protection in MS remain to be fully understood, VD immunomodulatory properties might appear crucial in mediating its effect. Long non-coding RNAs have been largely implicated in cancer pathogenesis and VD/VDRmediated protection in skin cancer. 7 Regulation of gene expression by lncRNAs involves different mechanisms, including epigenetic processes such as alteration of chromatin states. Accordingly, assuming that lncRNAs may function as key regulators for epigenetic transcriptional repression, HOTAIR and ANRIL lncRNAs have been shown to selectively bind to repressive polycomb complexes to execute histone modifications, thereby leading to transcriptional repression at specific loci. 23 In line with this, dosage in the expression levels of lncRNAs was strongly associated with H3K4me at promoter region. 24 Moreover, multiple lines of evidence have indicated that genes involved in VD functions can also be controlled by epigenetic mechanisms. 25 HOTAIR has been shown to exert pro-oncogenic actions on invasiveness and The expression level of HOTAIR significantly differs in patients with multiple sclerosis before vitamin D3 (VD3) supplementation versus controls in total and stratified groups based on gender (only in females) and serum VD concentration HOTAIR Expression (Delta Ct) Figure 2 . Analysis of the correlation between the expression levels of HOTAIR with clinical features of patients with multiple sclerosis (MS). Using Pearson and Spearman correlation tests, we did not find any significant correlation between the expression of HOTAIR with serum vitamin D (VD) level (a), Expanded Disability Status Scale (EDSS) score (b), disease duration (c) and age (d). These analyses were also performed for ANRIL long non-coding RNA (lncRNA) and were not statistically significant (P > 0Á05).
metastasis through alteration of histone H3K27 methylation 26 and, HOTAIR suppression sensitizes cells to tumour necrosis factor-a-induced apoptosis. Although lncRNAs, and more specifically HOTAIR, has been implicated in cancer pathogenesis, 27, 28 little is known about its expression and effect in immune-related diseases such as MS. Multiple sclerosis is a complex disease probably arising from interactions between genetic and environmental risk factors, with VD deficiency thought to play a major role. Knowing that VD function can be epigenetically regulated by lncRNAs and that several lncRNAs have been found dysregulated in the PBMCs of patients with MS, 9 we investigated the role of HOTAIR and ANRIL in VD-deficient and VD-supplemented patients with MS. To our knowledge, this is the first report of HOTAIR and ANRIL lncRNAs expression in patients with MS, and moreover, in the context of VD treatment. Interestingly, the expression level of HOTAIR was significantly higher in PBMCs from VD-deficient patients with MS before supplementation compared with healthy controls (P = 0Á004). This association did not remain significant after supplementation (P = 0Á068). Consistent with this result, Jiang et al. 7 have found overexpression of Hotair (4Á4-fold) in mouse keratinocyte/epidermis following VDR depletion, suggesting a functional impact of VD and VDR activation on HOTAIR expression. Although the precise mechanisms underlying VD regulation of HOTAIR expression in MS remain unknown, a possible mediation might involve c-Myc factor, which has been shown to mediate the effects of VD 29 and activate HOTAIR expression. 30 In line with this, we found a significant increase in the expression level of c-Myc after 100 nmol/ml VD supplementation for 24 hr. Moreover, with an area under the ROC curve of 0Á7, our finding further implies that HOTAIR expression levels in PBMCs may have a potentially predictive power to differentiate patients with MS from normal individuals.
Our data indicate an induction of HOTAIR lncRNA in MS and EAE; however, the consequences of such up-regulation in disease pathogenesis are still to be investigated. The observed reduction of HOTAIR in PBMCs from patients with MS after VD supplementation further suggests an implication of HOTAIR in VD effects. HOTAIR exerts its regulatory function through recruitment of the polycomb PRC complexes to specific loci and subsequent repressive histone post-translational modification. It has been shown that methylation at H3K27 by Ezh2 (a part of PRC2 complex) plays a role during the neuroglial development, promoting oligodendrocyte lineage rather than neuron and astrocyte differentiation. 31 The effect of Ezh2 in oligodendrocyte lineage appeared to be specific to the differentiation of oligodendrocyte progenitor cells to immature oligodendrocytes, as it down-regulated in mature oligodendrocytes at the onset of myelination. 32 In addition to central nervous system-related processes, studies have shown the role of PRC-like complexes in the mouse immune system responses and development of haematopoietic lineage. 33 For example, PRC-1-like complex seems to control a specific aspect of the genetic programme for T helper type 2 cell differentiation. 34 In addition to the well-known transcriptional repression of HOTAIR through chromatin redomelling, it has been recently shown that knockdown of HOTAIR can up-regulate miR-326 expression, 35 a T helper type 17-associated miRNA implicated in MS disease. 36 Therefore, HOTAIR can affect immune and neuroglial phenotypes, both being relevant processes in MS pathogenesis. Consistent with this, we found dysregulation of HOTAIR in both immune and nervous compartments in patients with MS and EAE mice, respectively. The differential expression of Hotair in the central nervous system of EAE mice, i.e. increased in the cerebellum and reduced in the spinal cord and cortex, implies a context-or tissue-specific regulation of Hotair lncRNA within the central nervous system and possibly between peripheral pathogenic cells such as PBMCs and the target organ. This further suggests different roles of Hotair depending on the inflammatory conditions and the tissue-specific target genes. Altogether, these findings suggest a possible role of HOTAIR in the pathogenesis of MS through various epigenetic mechanisms involving histone modification, chromatin remodelling or miRNA regulation both in central nervous system-related processes such as myelination and immune-related processes. Overall, these putative mechanisms are in line with the known immunomodulatory and neuroprotective action exerted by VD.
As previously mentioned, in a few patients the serum level of VD surprisingly decreased after supplementation. This might be associated with specific genetic variations that can reduce VDR mRNA stability and its expression. 37, 38 Moreover, we found a significant over-expression of HOTAIR in women with MS before VD treatment compared with controls, but this finding could not be observed in male patients. This suggests a gender-bias in the response to VD that could arise from interference with sexual hormones and further requires careful investigation in larger sample size cohorts. Interestingly, we found that supplementation of MS patients with VD led to a decrease in the expression level of VDR. This finding contrasts with previous studies reporting either induction of VDR transcript upon 1,25(OH) 2 D 3 exposure 39, 40 or an absence of effect from 1,25(OH) 2 D3 on VDR expression in mouse fibroblasts in vitro. 41 This discrepancy might be due to context-dependent and/or cell-type-specific effects of VD on its receptor.
Further in vitro investigation in THP-1 cells failed to find changes in the expression of HOTAIR and ANRIL after VD treatment or inflammation induction. However, THP-1 cells treated with rhGM-CSF, PHA or sera from patients with MS display a significant up-regulation of the pro-inflammatory IL-1b gene. This discrepancy in VD effect on the monocytic cell line THP-1 compared with PBMCs from patients with MS suggests a cell type-dependent role of HOTAIR in inflammatory processes, which might involve other immune cell types. This is further supported by the differential HOTAIR and ANRIL expression profiles in distinct immune cell types from the BioGPS data base (http://biogps.org. Here, we examined for the first time the role of VD in combination with lncRNAs in the pathogenesis of MS using in vivo, in vitro and in silico investigations. in the pathogenesis of MS. Overall, our data shed light on the immunomodulatory role of VD and reinforce the need to assess the efficacy of VD supplementation with regards to non-responders. Defining the effective dose, timing and duration of VD treatment of MS patients in co-administration with current medications may improve the therapeutic benefit for MS patients.
